These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23430197)

  • 1. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia.
    Kaji H; Imanishi Y; Sugimoto T; Seino S
    Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):440-4. PubMed ID: 21667439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism.
    Moosgaard B; Vestergaard P; Heickendorff L; Melsen F; Christiansen P; Mosekilde L
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):506-13. PubMed ID: 16268801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
    van Lierop AH; Witteveen JE; Hamdy NA; Papapoulos SE
    Eur J Endocrinol; 2010 Nov; 163(5):833-7. PubMed ID: 20817762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
    Rossini M; Viapiana O; Zanotti R; Tripi G; Perbellini O; Idolazzi L; Bonifacio M; Adami S; Gatti D
    Calcif Tissue Int; 2015 May; 96(5):410-6. PubMed ID: 25694360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density.
    Rossini M; Viapiana O; Adami S; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Orsolini G; Gatti D
    Clin Exp Rheumatol; 2015; 33(1):77-83. PubMed ID: 25438096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Rossini M; Adami S
    J Clin Endocrinol Metab; 2011 May; 96(5):1555-9. PubMed ID: 21367927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury.
    Wang W; Xu J; Liu K; Liu X; Li C; Cui C; Zhang Y; Li H
    Environ Toxicol Pharmacol; 2013 May; 35(3):402-7. PubMed ID: 23467116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.
    Ardawi MS; Al-Sibiany AM; Bakhsh TM; Rouzi AA; Qari MH
    Osteoporos Int; 2012 Jun; 23(6):1789-97. PubMed ID: 22041864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
    Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
    Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.